Dogwood Therapeutics Hits Midpoint in Phase 2b Trial for Halneuron® — Dogwood Therapeutics, Inc.

Event summary

Dogwood Therapeutics has enrolled over 50% of planned participants in its Phase 2b HALT-CINP trial for Halneuron®, with top-line results expected in Q3 2026.
Interim analysis shows a low dropout rate (4.3%) and preliminary evidence of pain reduction in patients treated with Halneuron® compared to placebo.
The study aims to evaluate Halneuron®'s efficacy in treating chemotherapy-induced neuropathic pain, a condition with no approved therapies.
Halneuron® has received FDA fast track designation for CINP treatment.

The big picture

Dogwood Therapeutics is advancing Halneuron®, a non-opioid analgesic targeting chemotherapy-induced neuropathic pain, an area with significant unmet medical need. The company's progress in the Phase 2b trial could validate its approach to treating chronic pain conditions, potentially opening up a substantial market opportunity. With backing from CK Life Sciences and support from the National Cancer Institute for its SP16 IV program, Dogwood is positioning itself as a key player in the biotech space focused on pain and neuropathy.

What we're watching

Clinical Efficacy: Whether Halneuron® can sustain its preliminary separation from placebo in the remaining trial participants.
Regulatory Pathway: The pace at which Dogwood Therapeutics advances Halneuron® through FDA approval processes if Phase 2b results are positive.
Market Opportunity: How successful trial results could position Halneuron® as a first-in-class therapy for chemotherapy-induced neuropathic pain.